Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13759903 | 1.00 | DPP4 (0.32) | DPP4CA12CA14TRPA1L3MBTL1 | |
| SCHEMBL23225998 | 0.86 | — | — | |
| SCHEMBL22017056 | 0.79 | PSENEN (0.34) | DPP4 | |
| SCHEMBL20996961 | 0.79 | PSENEN (0.34) | DPP4 | |
| SCHEMBL13792568 | 0.78 | TDP1 (0.32) | CA12CA14 | |
| SCHEMBL12597799 | 0.78 | CA12 (0.34) | CA12CA14TRPA1 | |
| SCHEMBL22872326 | 0.78 | CA12 (0.34) | CA12CA14TRPA1 | |
| SCHEMBL12250656 | 0.78 | CA12 (0.34) | CA12CA14TRPA1 | |
| SCHEMBL13788419 | 0.78 | DPP4 (0.31) | DPP4CA12CA14 | |
| SCHEMBL13686131 | 0.78 | TRPA1 (0.35) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-11702431-B2 | Oxo-substituted compound | Sumitomo Pharma Co., Ltd. (JP) | 2023-07-18 | — | — | US | disclosed |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-05-20 | — | — | US | disclosed |
| WO-2016050209-A1 | HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702431-B2 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | DPP4 999/4885CA12 3056/4885CA14 3053/4885 |
| US-20210147448-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | DPP4 999/4885CA12 3056/4885CA14 3053/4885 |
| US-20230287009-A1 | OXO-SUBSTITUTED COMPOUND | CYP51A1, OXA1L, O60361 | DPP4 999/4885CA12 3056/4885CA14 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.